Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Commissariat a l'Energie Atomique et aux Energies Alternatives

Research site

France 4 Place Du General Leclerc, 91401 Orsay, France

  • 3 trials recruiting
  • Depression · Epilepsy · Huntington's disease
  • Adults and children

About Specializations

Commissariat a l'Energie Atomique et aux Energies Alternatives in Orsay, France specialises in clinical trials of conditions such as Depression, Epilepsy, Huntington's disease, Multiple sclerosis, and other specialisations. This site conducts important research.

Main research areas of the site

Analytical, Diagnostic and Therapeutic Techniques and Equipment

The site specializes in cutting‑edge imaging, using 18F‑DPA‑714 PET imaging combined with MRI to enhance diagnostic accuracy and guide surgical decisions for neurological conditions.

  • PET‑MRI hybrid imaging
  • Neuroinflammation quantification
  • Pre‑operative seizure focus localisation

Collaboration with INFLANET supports multicentre studies that aim to refine imaging biomarkers and improve patient selection for advanced therapies.

Nervous System Diseases

Research at the centre targets multiple sclerosis and drug‑resistant epilepsy, seeking to better understand disease mechanisms and optimize treatment pathways.

  • White matter lesion assessment in MS
  • SEEG‑guided evaluation of surgical candidates
  • Neuroinflammatory biomarker development

Efforts led by Service Hospitalier Frederic Joliot aim to translate imaging insights into clearer diagnoses and more effective therapeutic strategies for patients.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
4 Place Du General Leclerc91401 OrsayFrance
Open in maps ↗
Recruiting now
3 trials
Conditions studied
4

More sites in OrsayFrance

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

4 clinical trials

Huntington's disease

Recruiting

Study on [18F]MNI-659 to Track Huntington's Disease Progression in Symptomatic and Pre-symptomatic Patients

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · Healthy volunteers
  • Substances:2-[2-[3-[4-(2-(18F)FLUORANYLETHOXY)PHENYL]-7-METHYL-4-OXOQUINAZOLIN-2-YL]ETHYL]-4-PROPAN-2-YLOXYISOINDOLE-1,3-DIONE
  • Sponsor:Assistance Publique Hopitaux De Paris

Multiple sclerosis

Recruiting

Study of [18F]-DPA-714 PET imaging to assess neuroinflammation in multiple sclerosis patients compared to healthy controls

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · Healthy volunteers
  • Substances:N,N-Diethyl-2-(2-(4-(2[(18)F]-Fluoroethoxy)Phenyl)5,7Dimethylpyrazolo[1,5A]Pyrimidin-3-Yl)Acetamide
  • Sponsor:Assistance Publique Hopitaux De Paris

Depression

Recruiting

Study on the Early Effects of Ketamine and Venlafaxine for Hospitalized Patients with Severe Major Depression

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Ketamine
  • Sponsor:Assistance Publique Hopitaux De Paris

Epilepsy

Not recruiting

Evaluation of 18F-DPA-714 PET-MRI imaging for locating epileptic focus in patients with drug-resistant partial epilepsy before surgery

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:N,N-Diethyl-2-(2-(4-(2[(18)F]-Fluoroethoxy)Phenyl)5,7Dimethylpyrazolo[1,5A]Pyrimidin-3-Yl)Acetamide
  • Sponsor:Commissariat a l'Energie Atomique et aux Energies Alternatives
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.